IPG Photonics (Nasdaq: IPGP) reported earnings on Oct. 31. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended Sep. 30 (Q3), IPG Photonics beat expectations on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue expanded significantly and GAAP earnings per share grew significantly.

Margins grew across the board.

Revenue details
 IPG Photonics reported revenue of $156.4 million. The 10 analysts polled by S&P Capital IQ hoped for sales of $150.8 million on the same basis. GAAP reported sales were 21% higher than the prior-year quarter's $129.1 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.81. The nine earnings estimates compiled by S&P Capital IQ predicted $0.80 per share. GAAP EPS of $0.81 for Q3 were 23% higher than the prior-year quarter's $0.66 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 55.0%, 40 basis points better than the prior-year quarter. Operating margin was 39.5%, 280 basis points better than the prior-year quarter. Net margin was 27.1%, 160 basis points better than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $148.8 million. On the bottom line, the average EPS estimate is $0.77.

Next year's average estimate for revenue is $562.7 million. The average EPS estimate is $2.93.

Investor sentiment
 The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,441 members out of 1,472 rating the stock outperform, and 31 members rating it underperform. Among 420 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 413 give IPG Photonics a green thumbs-up, and seven give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on IPG Photonics is outperform, with an average price target of $68.73.